Theorem Clinical Research, a US contract research organisation (CRO), has appointed Brian Bollwage to the position of vice president of global regulatory affairs.
Bollwage was previously director of global regulatory science at Bristol-Myers Squibb and executive director and regulatory counsel of global regulatory intelligence at i3 Research.
He is a food and drug law expert and a graduate of Rutgers Law School. He currently serves as an associate professor of food and drug law at Temple University in Philadelphia.
Theorem Clinical Research appoints vp of global regulatory affairs
Brian Bollwage is a food and drug law expert
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
![What Operation TrialBlazer means for CDMOs and CMC strategy]()
What Operation TrialBlazer means for CDMOs and CMC strategy
The FDA's new framework cuts Phase I data requirements, opens platform manufacturing data reuse and creates a new CRO/CDMO review role as HHS moves to close the gap with China's faster clinical trial pipeline — but how will this affect the pharma sector?
Manufacturing
![Piramal Pharma Solutions highlights strong performance across more than 200 customer audits]()
Piramal Pharma Solutions highlights strong performance across more than 200 customer audits
Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases